The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Orlistat, a New Lipase Inhibitor for the Management of Obesity
Open accessAbstract
Orlistat, a weight‐loss agent with a novel mechanism of action, recently was approved by the Food and Drug Administration for the treatment of obesity. It inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to decrease systemic absorption of dietary fat. In several trials lasting up to 2 years, orlistat was more effective than diet alone for weight reduction and maintenance of lost weight. Orlistat treatment also results in modest improvements in total cholesterol, low‐density lipoprotein, blood pressure, and fasting glucose and insulin concentrations. The major adverse effects are gastrointestinal, usually occur early in therapy, and tend to decrease with continued treatment. Because orlistat may decrease the absorption of fat‐soluble vitamins, a standard multiple‐vitamin supplement is recommended daily during therapy to prevent abnormalities in vitamin serum concentrations. The potential for severe gastrointestinal discomfort and the modest degree of weight loss may limit the agent's clinical utility. Its long‐term safety and effectiveness for weight maintenance, cost‐effectiveness of treatment, and overall reduction in obesity‐related morbidity and mortality remain to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Actual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Pi-Sunyer, F. X. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-7_part_2-199310011-00006 · Cited by 1,371
Beneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Current Estimates of the Economic Cost of Obesity in the United States
Wolf, A. M., & Colditz, G. A. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00322.x · Cited by 1,244
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 6×
“5% of those receiving placebo.(26) Subjects in the second study included 688 patients (average BMI 36 kg/m(2), average weight 99 kg) seen at obesity treatment centers throughout Europe.”
BackgroundMethodInfluentialHollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Rosenbaum, M., Leibel, R. L., & Hirsch, J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370606 · Cited by 584
Kuczmarski, R. J., Carroll, M. D., Flegal, K. M., & Troiano, R. P. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00575.x · Cited by 461
Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin
Hadváry, P., Lengsfeld, H., & Wolfer, H. (1988) · Biochemical Journal · doi:10.1042/bj2560357 · Cited by 345
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1108 · Cited by 287 · cited 1×
“The utility of orlistat for weight maintenance after conventional dieting was examined in a 1year study of obese subjects who were able to lose 8% or more of their initial body weight with a 6-month hypocaloric diet.(31) During the 6month weight-reduction period, 1313 otherwise healthy obese subjects (BMI 28–43 kg/m(2…”
MethodHadváry, P., Sidler, W., Meister, W., Vetter, W., & Wolfer, H. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52203-1 · Cited by 280
Borgström, B. (1988) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(88)90260-3 · Cited by 266
Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
Drent, M. L., Larsson, I., William-Olsson, T., QUAADE, F., Czubayko, F., von Bergmann, K., Strobel, W. M., Sjöström, L., & van der Veen, E. A. (1995) · PubMed · Cited by 208
Hauptman, J., Jeunet, F., & Hartmann, D. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.1.309s · Cited by 182
Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers
Zhi, J., Melia, A. T., Eggers, H., Joly, R., & Patel, I. H. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04034.x · Cited by 171
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
Gaal, L. F. V., Broom, J. I., Enzi, G., & Toplak, H. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050433 · Cited by 149
McNeely, W., & Benfield, P. (1998) · Drugs · doi:10.2165/00003495-199856020-00007 · Cited by 136
Treatment with orlistat reduces cardiovascular risk in obese patients
Zavoral, J. H. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816121-00024 · Cited by 121
Melia, A. T., Koss‐Twardy, S. G., & Zhi, J. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04230.x · Cited by 120
A one-year trial to assess the value of orlistat in the management of obesity.
James, W. P. T., Avenell, A., Broom, J. I., & Whitehead, J. (1997) · PubMed · Cited by 118
Tonstad, S., Pometta, D., Erkelens, D. W., Ose, L., Moccetti, T., Schouten, J. A., Golay, A., Reitsma, J. B., Bufalo, A. D., Pasotti, E., et al. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00191901 · Cited by 93
Metabolic Profiles of Minimally Absorbed Orlistat in Obese/Overweight Volunteers
Zhi, J., Melia, A. T., Funk, C., Viger, A., Gérard Hopfgartner, D., Lausecker, B., Wang, K., Fulton, J. S., Gabriel, L., & Mulligan, T. E. (1996) · The Journal of Clinical Pharmacology · doi:10.1177/009127009603601104 · Cited by 92
First Clinical Studies with Orlistat: A Short Review
Drent, M. L., & van der Veen, E. A. (1995) · Obesity Research · doi:10.1002/j.1550-8528.1995.tb00236.x · Cited by 82
Long‐Term Systemic Exposure of Orlistat, a Lipase Inhibitor, and Its Metabolites in Obese Patients
Zhi, J., Mulligan, T. E., & Hauptman, J. B. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007543 · Cited by 82
New approaches in the pharmacological treatment of obesity
Leonhardt, M., Hrupka, B. J., & Langhans, W. (1999) · European Journal of Nutrition · doi:10.1007/s003940050040 · Cited by 65
Zhi, J., Melia, A. T., Koss‐Twardy, S. G., Arora, S., & Patel, I. H. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04180.x · Cited by 65
Reitsma, J. B., Cabezas, M. C., de Bruin, T. W., & Erkelens, D. W. (1994) · Metabolism · doi:10.1016/0026-0495(94)90095-7 · Cited by 63
Ransac, S., Gargouri, Y., Moreau, H., & Verger, R. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16387.x · Cited by 60
Zhi, J., Melia, A. T., Guerciolini, R., Koss‐Twardy, S. G., Passe, S. M., Rakhit, A. K., & Sadowski, J. A. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04232.x · Cited by 46
Melia, A. T., Zhi, J., Koss‐Twardy, S. G., Min, B. H., Smith, B. L., Freundlich, N. L., Arora, S., & Passe, S. M. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04128.x · Cited by 39
The Effect of Orlistat on the Pharmacokinetics of Phenytoin in Healthy Volunteers
Melia, A. T., Mulligan, T. E., & Zhi, J. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04231.x · Cited by 35
Melia, A. T., Mulligan, T. E., & Zhi, J. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04211.x · Cited by 28
Influence of orlistat on the regulation of gallbladder contraction in man
Froehlich, F., Hartmann, D., Güzelhan, C., Gonvers, J. J., Jansen, J. B. �. �., & Fried, M. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02100135 · Cited by 21
The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers
Melia, A. T., Zhi, J., Zelasko, R., Hartmann, D., Güzelhan, C., Guerciolini, R., & Odink, J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050550 · Cited by 20
Is blockade of pancreatic lipase the answer?
Halsted, C. H. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1059 · Cited by 9
Lekkerkerker, J. F. F., Diemont, W. L., & Koopmans, P. P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)61301-3 · Cited by 4
Cited by
Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages
Huang, S. C.-C., Everts, B., Ivanova, Y., O'Sullivan, D., Nascimento, M., Smith, A. M., Beatty, W., Love-Gregory, L., Lam, W. Y., O'Neill, C. M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2956 · Cited by 1,214
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
Self-citationRegulation of intestinal lipid metabolism: current concepts and relevance to disease
Ko, C.-W., Qu, J., Black, D. D., & Tso, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0250-7 · Cited by 510
Lipase Inhibitors for Obesity: A Review
Liu, T.-T., Liu, X.-T., Chen, Q.-X., & Shi, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110314 · Cited by 403
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Metadata
- Authors
- Heck, A. M., Yanovski, J. A., & Calis, K. A.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2000-03
- Volume
- 20
- Issue
- 3
- Pages
- 270-279
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2030843949
- Cited by
- 572
- References
- 39
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.